secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2025-06-13T23:59:59+00:00
Accession:  0001193125-25-140739
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX stockholders approve amended equity plan adding 4.38M shares; three directors elected
--------------------------------------------------------------------------------

- Stockholders elected three Class I directors: Sean McCarthy (16.4M for), Mani Mohindru (19.7M for), Zhen Su (19.7M for), terms until 2028.
- Amended 2015 Equity Plan approved; shares available increase to 6,300,000 from prior pool plus 4,381,320 new shares.
- Employee Stock Purchase Plan amended to remove evergreen automatic increase and remove 10-year expiration, now indefinite.
- Ratified Ernst & Young as auditor for FY2025; advisory vote on exec compensation approved with ~22.9M for, 5.3M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525140739/0001193125-25-140739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312525140739/d948514d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-140739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer